top of page

Free Biopharma Daily Stock Updates - 02/17/22

$XBI $90.61 | -4.3%

 

Covid Updates

$NVAX -3.6% Health Canada Authorizes Novavax COVID-19 Vaccine source




Pipeline Updates

$AGIO -5.2% Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency source


$GRCL -5.3% Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma source


$CLSN -4.0% Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer source

$VERU -4.3% Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium source


$PSTX -15.2% Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium source


$AZN +0.3% Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants source


$ARWR -8.3% Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 source


$ALKS -5.4% Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium source


$EVLO -9.3% Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis source


$ENTA +2.4% ENANTA PHARMACEUTICALS ANNOUNCES PUBLICATION IN THE NEW ENGLAND JOURNAL OF MEDICINE OF DATA FROM THE PHASE 2A HUMAN CHALLENGE STUDY OF EDP-938 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) source



Business Updates

$SRNE -5.6% Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™ source



 

Posted by JM

0 comments
bottom of page